Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 17, Issue 12, 2010, Pages 845-850

  Sgier, C ^a   Mullhaupt B ^b   Gerlach, T ^c   Moradpour, D ^d   Negro, F ^e   Male P J ^e   Heim, M H ^f   Malinverni, R ^g   Cerny, A ^h   Dufour, J F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Hospital of St Gallen   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g Division of Rheumatology Neuchatel Hospital   (Switzerland)

^h Hospital of Lugano   (Switzerland)

Author keywords

apoptosis; cytokeratin; hepatitis C virus; M30

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CYTOKERATIN 18;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; DRUG RESPONSE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; VIREMIA; VIROLOGY;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; APOPTOSIS; COHORT STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; KERATIN-18; RECURRENCE; RNA, VIRAL; SWITZERLAND; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 77954659821     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01251.x     Document Type: Article

References (18)

1. Bantel H, Schulze-Osthoff K,. Apoptosis in hepatitis C virus infection. Cell Death Differ 2003; 10 (Suppl. 1): S48 - S58.
2. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 187: 567 - 572.
3. Schutte B, Henfling M, Kolgen W, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004; 297: 11 - 26.
4. Feldstein AE, Gores GJ,. An apoptosis biomarker goes to the HCV clinic. Hepatology 2004; 40: 1044 - 1046.
5. Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F,. Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem 2007; 40: 651 - 655.
6. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE,. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27 - 33.
7. Kronenberger B, Wagner M, Herrmann E, et al. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat 2005; 12: 307 - 314. (Pubitemid 40638039)
8. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078 - 1087.
9. Volkmann X, Cornberg M, Wedemeyer H, et al. Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 2006; 43: 1311 - 1316.
10. Kronenberger B, Zeuzem S, Sarrazin C, et al. Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antivir Ther 2007; 12: 779 - 787. (Pubitemid 47235492)
11. Canbay A, Friedman S, Gores GJ,. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39: 273 - 278.
12. Calabrese F, Pontisso P, Pettenazzo E, et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 2000; 31: 1153 - 1159.
13. Kronenberger B, Ruster B, Lee JH, et al. Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. J Hepatol 2000; 33: 640 - 647.
14. Bantel H, Lugering A, Poremba C, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001; 34: 758 - 767.
15. Balmer ML, Siegrist K, Zimmermann A, Dufour JF,. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009; 8: 1184 - 1188.
16. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK,. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366 - 371.
17. Marcellin P, Asselah T, Boyer N,. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47 - S56.
18. Perelson AS, Herrmann E, Micol F, Zeuzem S,. New kinetic models for the hepatitis C virus. Hepatology 2005; 42: 749 - 754.